On August 18, 2022, HALOZYME THERAPEUTICS, INC. (the Company) entered into Amendment No. 1 to the Credit Agreement (the Amendment) among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, BANK OF AMERICA, N.A., as Administrative Agent (in such capacity, the Administrative Agent) and swing line lender (in such capacity, the “Swing Line Lender”), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the Credit Agreement) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increases the size of the revolving credit facility from $350 million to $575 million.

The terms of the revolving credit facility are otherwise unchanged. Concurrently with the entry into the Amendment, the Company repaid the entire outstanding term loan facility and repaid all outstanding loans under the revolving credit facility under the Credit Agreement with a portion of the proceeds of its previously disclosed issuance of convertible notes.